We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+50.47%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$244M
Cap. Flow
+$79.7M
Cap. Flow %
14.07%
Top 10 Hldgs %
52.72%
Holding
83
New
26
Increased
22
Reduced
20
Closed
11
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$10.7M
2
SNY icon
Sanofi
SNY
+$9.45M
3
CCXI icon
ChemoCentryx, Inc.
CCXI
+$9.01M
4
PNTG icon
Pennant Group
PNTG
+$8.5M
5
MDCO
Medicines Co
MDCO
+$7.63M

Top Sells

Rank Stock Value
1
AMRN icon
Amarin Corp
AMRN
+$7.86M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.4M
3
ZGNX
Zogenix, Inc.
ZGNX
+$6.78M
4
DXCM icon
DexCom
DXCM
+$6.17M
5
ABMD
Abiomed Inc
ABMD
+$5.33M

Sector Composition

Rank Sector Weight
1 Healthcare 82.4%
2 Miscellaneous 13.14%
3 Real Estate 1.69%
4 Communication Services 1.29%
5 Industrials 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARGX icon
26
argenx
ARGX
$51.5B
$5.97M 1.05%
37,204
+1,200
+3% +$162K
2017 Q4
8 quarters
ILMN icon
27
Illumina
ILMN
$39.6B
$5.89M 1.04%
18,247
-9,252
-34% -$2.8M
2019 Q2
2 quarters
OXFD
28
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$5.81M 1.03%
349,823
+93,823
+37% +$1.52M
2019 Q3
1 quarter
RCM icon
29
DELISTED
R1 RCM Inc. Common Stock
RCM
$5.41M 0.96%
416,726
-309,246
-43% -$3.53M
2017 Q4
8 quarters
NTRA icon
30
Natera
NTRA
$56.7B
$5.29M 0.93%
+157,081
New +$5.79M
2019 Q4
0 quarters
KDMN
31
DELISTED
Kadmon Holdings, Inc.
KDMN
$5.17M 0.91%
+1,141,939
New +$4.18M
2019 Q4
0 quarters
GH icon
32
Guardant Health
GH
$21.3B
$5.06M 0.89%
+64,720
New +$4.66M
2019 Q4
0 quarters
QGEN icon
33
Qiagen
QGEN
$9.53B
$4.63M 0.82%
+129,199
New +$4.8M
2019 Q4
0 quarters
EHTH icon
34
eHealth
EHTH
$18.8M
$3.04M 0.54%
31,653
-11,000
-26% -$854K
2019 Q1
3 quarters
OHI icon
35
Omega Healthcare
OHI
$13.8B
$3.03M 0.53%
71,500
-35,000
-33% -$1.48M
2019 Q2
2 quarters
ELV icon
36
Elevance Health
ELV
$92.9B
$3.02M 0.53%
+10,000
New +$2.75M
2019 Q4
0 quarters
AGRX
37
DELISTED
Agile Therapeutics
AGRX
$2.84M 0.5%
568
+113
+25% +$395K
2019 Q3
1 quarter
XENE icon
38
Xenon Pharmaceuticals
XENE
$3.24B
$2.83M 0.5%
215,609
– –
2018 Q3
5 quarters
LTC icon
39
LTC Properties
LTC
$2.35B
$2.66M 0.47%
59,327
-10,000
-14% -$480K
2019 Q2
2 quarters
DXCM icon
40
DexCom
DXCM
$32.5B
$2.64M 0.47%
48,200
-130,000
-73% -$6.17M
2019 Q3
1 quarter
CNC icon
41
Centene
CNC
$34.2B
$2.51M 0.44%
+40,000
New +$2.17M
2019 Q4
0 quarters
IGMS icon
42
DELISTED
IGM Biosciences
IGMS
$2.47M 0.44%
+64,600
New +$1.62M
2019 Q4
0 quarters
AFMD icon
43
DELISTED
Affimed
AFMD
$2.35M 0.42%
85,777
+53,560
+166% +$1.43M
2018 Q1
7 quarters
COLL icon
44
Collegium Pharmaceutical
COLL
$755M
$2.29M 0.4%
111,361
-48,934
-31% -$816K
2019 Q2
2 quarters
CTRE icon
45
CareTrust REIT
CTRE
$8.64B
$2.24M 0.4%
107,464
-30,000
-22% -$656K
2017 Q4
8 quarters
BDSI
46
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.12M 0.37%
335,485
-372,535
-53% -$2.19M
2019 Q2
2 quarters
OTIC
47
DELISTED
Otonomy, Inc.
OTIC
$2.11M 0.37%
550,665
+174,323
+46% +$426K
2019 Q1
3 quarters
AQST icon
48
Aquestive Therapeutics
AQST
$474M
$2.04M 0.36%
+350,000
New +$1.82M
2019 Q4
0 quarters
HSKA
49
DELISTED
Heska Corp
HSKA
$1.99M 0.35%
20,771
-20,053
-49% -$1.74M
2019 Q1
3 quarters
ALBO
50
DELISTED
Albireo Pharma Inc
ALBO
$1.98M 0.35%
78,029
+60,000
+333% +$1.2M
2018 Q1
7 quarters
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Eversept Partners held 83 positions worth $566M, up 76% from $322M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Eversept Partners deployed $79.7M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Amarin Corp, an estimated $7.86M trimmed.

  • Eversept Partners's largest Q4 2019 buy was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
  • Eversept Partners added most to BioCryst Pharmaceuticals in Q4 2019, an estimated $10.7M increase.
  • Eversept Partners's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $7.86M.
  • Eversept Partners fully exited Alnylam Pharmaceuticals in Q4 2019, selling an estimated $7.4M.
  • Eversept Partners's ten largest holdings make up 53% of its $566M portfolio in Q4 2019.
  • Eversept Partners opened 26 new positions and closed 11 in Q4 2019.
  • Eversept Partners's portfolio value rose 76% quarter-over-quarter to $566M.

Based on Eversept Partners's 13F filing for Q4 2019, filed 13 Feb 2020.